Esperion Therapeutics | ESPR - Заемный капитал





Заемный капитал Изменить Дата
AbbVie USD 62.97B 12M 2025-09
Alnylam Pharmaceuticals USD 2.48B 1.44B 2025-12
Alterity Therapeutics Limited AUD 43.68K 59.53K 2025-12
Amgen USD 50B 2.43B 2025-12
Biogen USD 6.29B 1.4M 2025-09
BioMarin Pharmaceutical USD 597.18M 513K 2025-12
Cipla INR 2.98B 454.6M 2025-09
CSL USD 10.42B 273M 2025-12
Cytokinetics USD 1.12B 957.23M 2025-12
Daiichi Sankyo JPY 300.15B 199.41B 2025-12
Eli Lilly USD 40.87B 5.6M 2025-12
Esperion Therapeutics USD 457.65M 9.5M 2025-12
Geron USD 119.55M 283K 2025-12
Grifols EUR 9.95B 722.93M 2025-12
Halozyme Therapeutics USD 2.14B 1.34B 2025-12
Heron Therapeutics USD 140.64M 975K 2025-12
Ionis Pharmaceuticals USD 1.9B 1.87B 2025-12
Merck USD 39.97B 6B 2025-09
Minerva Neurosciences USD 0 86.58M 2024-09
Moderna USD 610M 584M 2025-12
Nektar Therapeutics USD 63.16M 44.35M 2025-12
Pfizer USD 57.41B 93M 2025-09
PTC Therapeutics USD 2.03B 193.22M 2025-12
Puma Biotechnology USD 10.87M 222K 2025-06
Regeneron Pharmaceuticals USD 2.71B 720.4M 2025-12
Sanofi EUR 15.72B 2.45B 2025-12
Sarepta Therapeutics USD 828.97M 206.17M 2025-12
United Therapeutics USD 100M 100M 2024-06
Vanda Pharmaceuticals USD 3.15M 3.15M 2024-12